Varicella zoster virus (VZV) vaccine
AssigneeModernaTX, Inc.
InventorGiuseppe Ciaramella
Life of this patent
Estimating the term…
Abstract
Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
Claims20
A composition comprising an RNA polynucleotide having an open reading frame encoding a varicella zoster virus (VZV) polypeptide, wherein the VZV polypeptide comprises VZV gE or gI, formulated in a lipid nanoparticle comprising 20-60 mol % cationic lipid, 5-25 mol % neutral lipid, 25-55 mol % cholesterol, and 0.5-15 mol % polyethylene glycol (PEG)-modified lipid, wherein the ionizable cationic lipid comprises Compound 25:
Dependencies are inferred from the claim text.